Skip to content
aiqbench takeAI Research

aiqbench analysis

Vilya-2 represents a significant advancement in AI-driven structural biology by utilizing diffusion transformers to accurately model complex peptide-protein interactions that previous co-evolutionary models could not handle effectively. This tool enables high-fidelity prediction of diverse molecular interfaces, including macrocycles and small molecules, which is critical for accelerating de novo therapeutic design pipelines beyond traditional protein-only applications.
Sources coveringarXiv, Fortune
What this isA model's reading of the article and related coverage, written for aiqbench. Not the publisher's words.

Accurate structural modeling of chemically diverse molecular interfaces with Vilya-2

arXiv3 min read

arXiv:2607.25156v1 Announce Type: new Abstract: Structure-prediction networks built on co-evolutionary statistics have transformed protein-based drug discovery, yet their accuracy does not extend to peptide therapeutics--an increasingly important modality defined by non-canonical residues, macrocyclization, and complex topologies. We introduce Vilya-2, a diffusion transformer that extends the all-atom representation of Vilya-1 from modeling individual molecules to modeling their interactions with protein targets. This all-atom representation enables transfer learning between different molecular types, and delivers highly accurate structural modeling of peptides across sizes, classes, and compositions bound to therapeutically relevant targets. By generating diverse structural ensembles and ranking them with calibrated confidence, Vilya-2 recovers 59.1% of peptide interfaces to sub-2 {\AA} backbone RMSD, far exceeding the performance of a representative co-folding model even when that model is given the bound receptor as a template. In addition, Vilya-2 is state-of-the-art at small-molecule docking, and generalizes to novel protein-small molecule complexes unlike those seen in training. It also generalizes to modeling molecular conformations of diverse macrocycles and disulfide-stapled miniproteins several-fold larger than any molecule seen in training. Finally, Vilya-2 can be used as a foundation model, and fine-tuned to enrich for active compounds in hit-to-lead campaigns. By unifying predictive accuracy with broad generalizability across chemical space, Vilya-2 is the structure-prediction oracle that de novo peptide design pipelines require--establishing the all-atom approach as a general foundation for the design and evaluation of de novo peptide therapeutics.

Authors:Vilya Research: Pascal Sturmfels, Naozumi Hiranuma, Milad Salem, Benjamin D. Sellers, Stephen Rettie, CJ San Felipe, Chase A. P. Wood, Jeffrey K. Holden, Adam P. Moyer, Patrick J. Salveson, Ivan Anishchanka

Abstract:Structure-prediction networks built on co-evolutionary statistics have transformed protein-based drug discovery, yet their accuracy does not extend to peptide therapeutics--an increasingly important modality defined by non-canonical residues, macrocyclization, and complex topologies. We introduce Vilya-2, a diffusion transformer that extends the all-atom representation of Vilya-1 from modeling individual molecules to modeling their interactions with protein targets. This all-atom representation enables transfer learning between different molecular types, and delivers highly accurate structural modeling of peptides across sizes, classes, and compositions bound to therapeutically relevant targets. By generating diverse structural ensembles and ranking them with calibrated confidence, Vilya-2 recovers 59.1% of peptide interfaces to sub-2 Å backbone RMSD, far exceeding the performance of a representative co-folding model even when that model is given the bound receptor as a template. In addition, Vilya-2 is state-of-the-art at small-molecule docking, and generalizes to novel protein-small molecule complexes unlike those seen in training. It also generalizes to modeling molecular conformations of diverse macrocycles and disulfide-stapled miniproteins several-fold larger than any molecule seen in training. Finally, Vilya-2 can be used as a foundation model, and fine-tuned to enrich for active compounds in hit-to-lead campaigns. By unifying predictive accuracy with broad generalizability across chemical space, Vilya-2 is the structure-prediction oracle that de novo peptide design pipelines require--establishing the all-atom approach as a general foundation for the design and evaluation of de novo peptide therapeutics.

Machine Learning (cs.LG)

arXiv:2607.25156 [cs.LG]

(or arXiv:2607.25156v1 [cs.LG] for this version)

https://doi.org/10.48550/arXiv.2607.25156 arXiv-issued DOI via DataCite (pending registration)

Full text under the publisher's open licence · 274 words

Related coverage